A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.
暂无分享,去创建一个
J. Maciejewski | M. Egorin | Y. Saunthararajah | A. Advani | M. Sekeres | Barbara Tripp | M. Kalaycio | J. Bates | E. Hsi | E. Copelan | R. Sobecks | R. Tiu | C. Cotta | A. Salvado | M. Howard | T. Jin | C. Price | Kathleen Lim | M. L. Rush | E. Noon
[1] M. McDevitt,et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.
[2] P. Chevallier,et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Advani,et al. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. , 2008, Leukemia research.
[4] J. Friedberg,et al. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. , 2006, Leukemia research.
[5] E. Vellenga,et al. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. , 2007, Blood.
[6] M. Caligiuri,et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. , 2007, Blood.
[7] H. Döhner,et al. Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib , 2007, Cancer.
[8] E. Heiss,et al. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. , 2006, The Biochemical journal.
[9] M. Gallucci,et al. Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Marx,et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.
[11] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Egorin,et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[13] A. Venditti,et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.
[14] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[15] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[16] Vera Bittner,et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. , 2002, Heart & lung : the journal of critical care.
[17] C. Hans,et al. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia. , 2002, American journal of clinical pathology.
[18] T. Robak,et al. The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.
[19] I. Weissman,et al. Hematopoietic Stem Cells Need Two Signals to Prevent Apoptosis; Bcl-2 Can Provide One of These, Kitl/C-KIT Signaling the Other , 2000, The Journal of experimental medicine.
[20] C. L. Perkins,et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. , 2000, Blood.
[21] D. Linnekin,et al. Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.